In 2017, dramatic advances have been made in the treatment of motor neuron diseases. New therapies have been approved for spinal muscular atrophy and amyotrophic lateral sclerosis, and a host of other therapies that are currently under development are showing promising results.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Eisen, A. et al. Cortical influences drive amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 88, 917–924 (2017).
Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).
The Writing Group. Safety and efficacy of edaravone inwell defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505–512 (2017).
Mora, J. S., Barbeito, L. & Hermine, O. Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: results from a randomized controlled phase 3 trial. European Network to Cure ALS (ENCALS) http://videolectures.net/encals2017_barbeito_mora_hermine_therapy/ (2017).
Meininger, V. et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 16, 208–216 (2017).
van Eijk, R. P. A. et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2017-317077 (2017).
McLaughlin, R. L. et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat. Commun. 8, 14774 (2017).
Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942–955 (2011).
Turner, M. R. & Kiernan, M. C. The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder. J. Neurol. Neurosurg. Psychiatry 86, 481–482 (2015).
van Eijk, R. P. A., et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 89, 1915–1922 (2017).
M.C.K. is supported by funding from the National Health and Medical Research Council of Australia (Program Grant #1037746).
The author declares no competing financial interests.
About this article
Cite this article
Kiernan, M. Progress towards therapy in motor neuron disease. Nat Rev Neurol 14, 65–66 (2018). https://doi.org/10.1038/nrneurol.2017.186
Medicinal Research Reviews (2020)
International Journal of Molecular Sciences (2019)
Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS)
Pharmacology & Therapeutics (2019)
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2019)
Frontiers in Neuroscience (2019)